Voya Investment Management LLC raised its holdings in shares of MacroGenics, Inc. (NASDAQ:MGNX) by 3.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 361,633 shares of the biopharmaceutical company’s stock after buying an additional 11,194 shares during the period. Voya Investment Management LLC owned about 0.98% of MacroGenics worth $6,332,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of MGNX. Dimensional Fund Advisors LP lifted its position in shares of MacroGenics by 314.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 180,739 shares of the biopharmaceutical company’s stock valued at $3,165,000 after acquiring an additional 137,167 shares in the last quarter. Hood River Capital Management LLC lifted its position in shares of MacroGenics by 2.3% in the 2nd quarter. Hood River Capital Management LLC now owns 576,193 shares of the biopharmaceutical company’s stock valued at $10,089,000 after acquiring an additional 13,050 shares in the last quarter. Virtu KCG Holdings LLC purchased a new stake in shares of MacroGenics in the 2nd quarter valued at approximately $232,000. Parametric Portfolio Associates LLC purchased a new stake in shares of MacroGenics in the 2nd quarter valued at approximately $203,000. Finally, BB Biotech AG lifted its position in shares of MacroGenics by 4.0% in the 2nd quarter. BB Biotech AG now owns 2,350,112 shares of the biopharmaceutical company’s stock valued at $41,150,000 after acquiring an additional 90,112 shares in the last quarter. Hedge funds and other institutional investors own 84.47% of the company’s stock.
MacroGenics, Inc. (MGNX) opened at 17.53 on Wednesday. MacroGenics, Inc. has a 1-year low of $14.36 and a 1-year high of $31.85. The company has a 50-day moving average of $17.73 and a 200-day moving average of $18.18. The firm’s market capitalization is $645.07 million.
MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by ($0.09). MacroGenics had a negative return on equity of 56.81% and a negative net margin of 1,216.51%. The firm had revenue of $1.70 million for the quarter, compared to the consensus estimate of $15.82 million. During the same period last year, the company posted $1.12 earnings per share. The business’s revenue was down 97.9% compared to the same quarter last year. On average, equities analysts predict that MacroGenics, Inc. will post ($4.42) earnings per share for the current year.
Several equities research analysts recently commented on MGNX shares. SunTrust Banks, Inc. restated a “buy” rating and issued a $26.00 price target on shares of MacroGenics in a research report on Friday, September 1st. Zacks Investment Research downgraded shares of MacroGenics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. Wedbush reiterated an “outperform” rating and issued a $44.00 target price on shares of MacroGenics in a research report on Monday, September 11th. ValuEngine upgraded shares of MacroGenics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Finally, BidaskClub downgraded shares of MacroGenics from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Three analysts have rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $30.30.
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
Want to see what other hedge funds are holding MGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MacroGenics, Inc. (NASDAQ:MGNX).
Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.